YU81203A - Pojedinačna doza inhibitora aromataze za lečenje neplodnosti - Google Patents
Pojedinačna doza inhibitora aromataze za lečenje neplodnostiInfo
- Publication number
- YU81203A YU81203A YU81203A YUP81203A YU81203A YU 81203 A YU81203 A YU 81203A YU 81203 A YU81203 A YU 81203A YU P81203 A YUP81203 A YU P81203A YU 81203 A YU81203 A YU 81203A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- aromatase inhibitor
- single dose
- female
- fsh
- medicament
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Upotreba inhibitora aromataze (AI) u preparatu leka za koriscenje za indukciju ovulacije kod zena koje pate od anovulatorne neplodnosti, sto obuhvata davanje takvoj pacijentkinji pojedinacne doze najmanje jednog inhibitora aromataze. Upotreba inhibitora aromataze (AI) za pripremu leka koji obuhvata pojedinacnu dozu najmanje jednog inhibitora aromataze (AI) za davanje ovulirajucoj zeni koja pati od neobjasnjene neplodnosti ili drugih tipova ovulatorne neoplodnosti pocetkom jednog ili vise menstrualnih ciklusa. Ovakav lek se moze davati i anovulatornoj zeni u kombinaciji sa vise doza hormona za stimulaciju folikula (FSH) gde se doza FSH moze smanjiti. Otkriva se i upotreba AI za pripremu preparata za davanje zenama koje lose reaguju na FSH, sto obuhvata kombinaciju pojedinacne doze AI sa vise doza FSH. Opisuju se i odgovarajuci farmaceutski preparati i pakovanja.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28428201P | 2001-04-17 | 2001-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU81203A true YU81203A (sh) | 2006-05-25 |
Family
ID=23089583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU81203A YU81203A (sh) | 2001-04-17 | 2002-04-17 | Pojedinačna doza inhibitora aromataze za lečenje neplodnosti |
Country Status (32)
Country | Link |
---|---|
US (1) | US8008333B2 (sh) |
EP (1) | EP1383578B1 (sh) |
JP (1) | JP2004529924A (sh) |
KR (1) | KR20040025916A (sh) |
CN (1) | CN1551789A (sh) |
AR (1) | AR034036A1 (sh) |
AT (1) | ATE409066T1 (sh) |
AU (1) | AU2002249043B2 (sh) |
BG (1) | BG108323A (sh) |
BR (1) | BR0208920A (sh) |
CA (1) | CA2444980C (sh) |
CY (1) | CY1108648T1 (sh) |
CZ (1) | CZ20033107A3 (sh) |
DE (1) | DE60229047D1 (sh) |
DK (1) | DK1383578T3 (sh) |
EA (1) | EA011310B1 (sh) |
EE (1) | EE200300505A (sh) |
ES (1) | ES2311599T3 (sh) |
HR (1) | HRP20030839A2 (sh) |
HU (1) | HUP0304003A2 (sh) |
IL (1) | IL158396A0 (sh) |
MX (1) | MXPA03009447A (sh) |
NO (1) | NO20034246L (sh) |
NZ (1) | NZ552873A (sh) |
PL (1) | PL366744A1 (sh) |
PT (1) | PT1383578E (sh) |
SI (1) | SI1383578T1 (sh) |
SK (1) | SK14242003A3 (sh) |
UA (1) | UA82648C2 (sh) |
WO (1) | WO2002083241A1 (sh) |
YU (1) | YU81203A (sh) |
ZA (1) | ZA200307516B (sh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004004634A2 (en) * | 2002-07-02 | 2004-01-15 | Pharmacia & Upjohn Company Llc | Infertility treatment with exemestane |
CA2619503A1 (en) * | 2005-06-28 | 2007-01-04 | Robert F. Casper | Aromatase inhibitors for emergency contraception |
AU2007204969A1 (en) * | 2006-01-10 | 2007-07-19 | Cortendo Invest Ab | Methods and compositions for treating prostate cancer |
WO2011143752A1 (en) * | 2010-05-20 | 2011-11-24 | University Of Saskatchewan | Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal |
US10004723B2 (en) | 2013-04-19 | 2018-06-26 | University Of Saskatchewan | Aromatase inhibitor-releasing intravaginal device |
US20160022644A1 (en) * | 2014-07-22 | 2016-01-28 | Tsu-I Catherine Wang | Oral Transmucosal Compositions Including Aromatase Inhibitors for Treating Female Infertility |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4728645A (en) * | 1982-12-21 | 1988-03-01 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors |
US4602025A (en) * | 1984-06-18 | 1986-07-22 | Eli Lilly And Company | Aromatase inhibitors |
US4845227A (en) * | 1984-06-18 | 1989-07-04 | Eli Lilly And Company | Aromatase inhibitors from azoles |
US4978672A (en) * | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
GB8726505D0 (en) * | 1987-11-12 | 1987-12-16 | Ici Plc | Naphtho(2 1-b)furan derivatives |
DE4330237C2 (de) | 1993-09-02 | 1995-11-30 | Schering Ag | 1-Methylsubstituierte Androsta-1,4-dien-3,17-dione, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate |
US6015789A (en) * | 1996-04-30 | 2000-01-18 | Takeda Chemical Industries, Ltd. | Combined use of GnRH agonist and antagonist |
DE19622457A1 (de) | 1996-05-24 | 1997-11-27 | Schering Ag | 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
US6953774B2 (en) * | 2000-08-11 | 2005-10-11 | Applied Research Systems Ars Holding N.V. | Methods of inducing ovulation |
-
2002
- 2002-04-17 AT AT02717919T patent/ATE409066T1/de active
- 2002-04-17 DE DE60229047T patent/DE60229047D1/de not_active Expired - Lifetime
- 2002-04-17 IL IL15839602A patent/IL158396A0/xx unknown
- 2002-04-17 SK SK1424-2003A patent/SK14242003A3/sk unknown
- 2002-04-17 DK DK02717919T patent/DK1383578T3/da active
- 2002-04-17 NZ NZ552873A patent/NZ552873A/en not_active IP Right Cessation
- 2002-04-17 CN CNA028120825A patent/CN1551789A/zh active Pending
- 2002-04-17 YU YU81203A patent/YU81203A/sh unknown
- 2002-04-17 SI SI200230747T patent/SI1383578T1/sl unknown
- 2002-04-17 MX MXPA03009447A patent/MXPA03009447A/es not_active Application Discontinuation
- 2002-04-17 ES ES02717919T patent/ES2311599T3/es not_active Expired - Lifetime
- 2002-04-17 PL PL02366744A patent/PL366744A1/xx not_active Application Discontinuation
- 2002-04-17 EE EEP200300505A patent/EE200300505A/xx unknown
- 2002-04-17 BR BR0208920-3A patent/BR0208920A/pt not_active IP Right Cessation
- 2002-04-17 WO PCT/CA2002/000527 patent/WO2002083241A1/en active IP Right Grant
- 2002-04-17 PT PT02717919T patent/PT1383578E/pt unknown
- 2002-04-17 CZ CZ20033107A patent/CZ20033107A3/cs unknown
- 2002-04-17 AR ARP020101399A patent/AR034036A1/es unknown
- 2002-04-17 UA UA20031110268A patent/UA82648C2/uk unknown
- 2002-04-17 AU AU2002249043A patent/AU2002249043B2/en not_active Ceased
- 2002-04-17 EA EA200301128A patent/EA011310B1/ru not_active IP Right Cessation
- 2002-04-17 KR KR10-2003-7013484A patent/KR20040025916A/ko not_active Application Discontinuation
- 2002-04-17 CA CA2444980A patent/CA2444980C/en not_active Expired - Fee Related
- 2002-04-17 JP JP2002581041A patent/JP2004529924A/ja active Pending
- 2002-04-17 EP EP02717919A patent/EP1383578B1/en not_active Expired - Lifetime
- 2002-04-17 HU HU0304003A patent/HUP0304003A2/hu unknown
- 2002-04-17 US US10/475,101 patent/US8008333B2/en not_active Expired - Fee Related
-
2003
- 2003-09-23 NO NO20034246A patent/NO20034246L/no not_active Application Discontinuation
- 2003-09-26 ZA ZA200307516A patent/ZA200307516B/en unknown
- 2003-10-15 HR HR20030839A patent/HRP20030839A2/hr not_active Application Discontinuation
- 2003-11-07 BG BG108323A patent/BG108323A/bg unknown
-
2008
- 2008-12-12 CY CY20081101446T patent/CY1108648T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mitwally et al. | Single-dose administration of an aromatase inhibitor for ovarian stimulation | |
US6265393B1 (en) | Prevention of endometriosis signs or symptons | |
NO964089D0 (no) | Farmasöytisk kombinasjonspreparat for hormonal konsentrasjon | |
BR9909672A (pt) | uso de um composto medicinal ativo no preparo de um medicamento para o tratamento de hipertensão | |
PL338982A1 (en) | Drug for improving duration of muscle action or for treating muscular disorders or diseases | |
de Ziegler et al. | Synchronization of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation (COH). | |
SG146638A1 (en) | Pharmaceutical delivery system | |
Almen-Christensson et al. | Prevention of menstrual migraine with perimenstrual transdermal 17-β-estradiol: a randomized, placebo-controlled, double-blind crossover study | |
MX173567B (es) | Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih | |
CY1108648T1 (el) | Αναστολεας της αρωματασης σε μια δοση για την θεραπευτικη αντιμετωπιση της υπογόνιμοτήτας | |
BR0208955A (pt) | Inibidores de aromatase para tratamento de infertilidade | |
RU2449796C9 (ru) | Фармацевтическая комбинация этинилэстрадиола и дроспиренона для использования в качестве контрацептива | |
CA2361081A1 (en) | Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis | |
JP2004529924A5 (sh) | ||
IL122659A0 (en) | Medical use of certain angiotensin II type receptor antagonists | |
BR0305033A (pt) | Uso de uma substância tendo atividade de hormÈnio luteinizante (substância lh), e, kit farmacêutico | |
BG63363B1 (bg) | Използване на антагонист на gnrh за получаване нафармацевтичен състав за лечение на гонадостероидно зависими заболявания | |
YU81303A (sh) | Inhibicija aromatazom u cilju poboljšanja asistirane reprodukcije | |
UA51627C2 (uk) | Відновлення тонічної секреції естрогену з яєчників для довгочасних схем лікування | |
Adashi | The morning after: novel hormonal approaches to postcoital interception | |
US20220313705A1 (en) | Cyproterone acetate compositions and uses thereof | |
Davar et al. | Comparison of the success rate of letrozole and clomiphene citrate in women undergoing intrauterine insemination | |
CA2403674A1 (en) | The use of t3 for treating congestive heart failure | |
Mouanness et al. | Elagolix Represents a Less Invasive and Cheaper Option Than Injectable GnRH Antagonist for Ovulation Suppression in IVF | |
King | AZT delta study: major European/Australian study finds combinations better than AZT alone |